Life Science Big News Roundup: Relevium Announces Intention to Spin-Out Pediatric Cannabis Subsidiary; BriaCell Announces Remarkable Responder in Combination Study with KEYTRUDA®; Avricore and Clinart MENA Announce Interim Agreement for HealthTab™ + RASTR Network
In case you missed it, here is this week’s life science big news roundup.
XORTX Reports Positive Phase 2 Results in Type 2 Diabetic Nephorpathy
XORTX Therapeutics (CSE:XRX, OTCQB:XRTXF) has announced results from its US Phase 2 clinical trial in patients with type 2 diabetic...
Adamas Announces Data for GOCOVRI in Parkinson’s Disease
Adamas Pharmaceuticals (NASDAQ:ADMS) has announced presentation of new data on GOCOVRI to treat dyskinesia in patients with Parkinson’s disease. As...
BriaCell Announces Private Placement of up to $600,000
BriaCell is pleased to announce a non-brokered private placement of up to approximately 8,571,428 common shares in the capital of...
Foamix Enrolls First Patient in Phase 2 Acne Clinical Trial
There will be approximately 400 patients enrolled in the trial aged 12 years and older with moderate-to-severe acne.
PDS Biotechnology Reports Clinical Data for Novel Immunotherapy PDS101
According to the company, 60 percent of evaluable patients exhibited a clinical response in the study. Activity was observed at...
Rafael Pharma Expands Phase 3 Trial into South Korea
The clinical trials will kick off with an investigator meeting held on Sept. 19 in Seoul. The study is also...